{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","groups":[{"description":"Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols.\n\nFilgrastim: Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days\n\nPlerixafor: Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight\n\nApheresis: The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 10\\^6 CD34+ cells/kg.","id":"OG000","title":"Hematopoietic Progenitor Cells (HPC)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"27 months and 27 days","title":"Number of Participants With Serious and Non-Serious Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}